05:04 PM EDT, 10/15/2024 (MT Newswires) -- UroGen Pharma ( URGN ) said Tuesday the US Food and Drug Administration accepted the new drug application for UGN-102 as an intravesical solution to treat low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA has set a Prescription Drug User Fee Act target action date of June 13, 2025, the company said. The...

Oct 15 (Reuters) - aTyr Pharma Inc ( ATYR ): * POINT72 ASSET MANAGEMENT, L.P. REPORTS 6.2% PASSIVE STAKE IN ATYR PHARMA AS OF OCT 14 - SEC FILING Source text for Eikon: Further company coverage: ...

Oct 15 (Reuters) - New York Community Bancorp ( NYCB/PA ) said on Tuesday it has changed its name to Flagstar Financial and its stock symbol to FLG. ...

Biodexa Pharmaceuticals Plc ( BDRX ) shares are soaring in Tuesday’s after-hours session following the company’s announcement that it was granted an extension to demonstrate compliance with Nasdaq listing requirements. What Happened: Biodexa announced Tuesday the Nasdaq Hearings Panel approved the company’s request for an extension to demonstrate compliance with the $1 minimum bid price requirement for continued listing. The company announced...